(NASDAQ: ODTX) Odyssey Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.59%.
Odyssey Therapeutics's earnings in 2026 is N/A.On average, 9 Wall Street analysts forecast ODTX's earnings for 2026 to be -$297,045,059, with the lowest ODTX earnings forecast at -$344,819,722, and the highest ODTX earnings forecast at -$275,068,426. On average, 10 Wall Street analysts forecast ODTX's earnings for 2027 to be -$231,480,475, with the lowest ODTX earnings forecast at -$331,629,897, and the highest ODTX earnings forecast at -$177,658,873.
In 2028, ODTX is forecast to generate -$210,397,904 in earnings, with the lowest earnings forecast at -$270,391,422 and the highest earnings forecast at -$141,824,271.